Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer.

NCT03403777 is registered in ClinicalTrials.gov with National Cancer Institute, Slovakia as lead sponsor.

NCT NCT03403777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03403777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer.
Lead sponsor
National Cancer Institute, Slovakia
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2017
Completion date
February 28, 2019
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, gonadal disorders, molecular mechanisms of pharmacological action, neoplasms, neoplasms, germ cell and embryonal, testicular diseases, testicular neoplasms